Soroush Mana Pharmed

As of July 2019, SMpharmed disintegrated from Hasti Aria Shimi (initial company). Soroush Mana Pharmed Company (SMpharmed) started its activity as a subsidiary of Golrang pharmaceutical investment (GPI) early 2019 with a research-production approach. As of July 2019, SMpharmed disintegrated from Hasti Aria Shimi (initial company) and started operating under the brand of SMPharmed. Our Mission & Vision The company aims at self-sufficiency in the production of pharmaceutical raw materials and promotes the quality of health services with an innovative method of supply and services. Our mission and vision are based on the four following concepts: Providing technical knowledge of pharmaceutical APIs to local medicine manufacturers; Developing the specifications of products` portfolio to enter the global market; Promoting the quality of products based on world standards and GMP regulations; Improvement and elimination of manufacturing barriers for Golrang member pharmaceutical subsidiaries by utilizing formulations, production of intermediates and imported reagents; SMPharmed's long-term strategy is to supply premium quality products to the domestic and global markets. Our Achievements We have achieved significant accomplishments by relying on local experts, using low-cost methods in the manufacture of effective pharmaceutical APIs and new formulation practices. One of these achievements is the technical know-how of producing level one knowledge-based APIs such as Nalbuphine HCl, Naltrexone HCl, Tetrabenazine, and Duloxetine HCl, and level two knowledge-based APIs such as Pregabalin, Deferrazirox, and Methyl Vinyl Ketone. Other remarkable efforts include technical know-how in the production of Buprenorphine HCl, Methadone HCl, and Volcanoine Monohydrate to complement our narcotic portfolio. In the field of commercialized medicines, two formulations of Noscapine Syrup and Opium Tincture are available for sale.